These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 30142160)

  • 1. A dual-specific macrophage colony-stimulating factor antagonist of c-FMS and αvβ3 integrin for osteoporosis therapy.
    Zur Y; Rosenfeld L; Keshelman CA; Dalal N; Guterman-Ram G; Orenbuch A; Einav Y; Levaot N; Papo N
    PLoS Biol; 2018 Aug; 16(8):e2002979. PubMed ID: 30142160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. c-Fms signaling mediates neurofibromatosis Type-1 osteoclast gain-in-functions.
    He Y; Rhodes SD; Chen S; Wu X; Yuan J; Yang X; Jiang L; Li X; Takahashi N; Xu M; Mohammad KS; Guise TA; Yang FC
    PLoS One; 2012; 7(11):e46900. PubMed ID: 23144792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2-(trimethylammonium) ethyl (R)-3-methoxy-3-oxo-2-stearamidopropyl phosphate suppresses osteoclast maturation and bone resorption by targeting macrophage-colony stimulating factor signaling.
    Park SJ; Park DR; Bhattarai D; Lee K; Kim J; Bae YS; Lee SY
    Mol Cells; 2014 Aug; 37(8):628-35. PubMed ID: 25139265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineering a monomeric variant of macrophage colony-stimulating factor (M-CSF) that antagonizes the c-FMS receptor.
    Zur Y; Rosenfeld L; Bakhman A; Ilic S; Hayun H; Shahar A; Akabayov B; Kosloff M; Levaot N; Papo N
    Biochem J; 2017 Jul; 474(15):2601-2617. PubMed ID: 28655719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DICAM inhibits osteoclast differentiation through attenuation of the integrin αVβ3 pathway.
    Jung YK; Han SW; Kim GW; Jeong JH; Kim HJ; Choi JY
    J Bone Miner Res; 2012 Sep; 27(9):2024-34. PubMed ID: 22492581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blocking of the Ubiquitin-Proteasome System Prevents Inflammation-Induced Bone Loss by Accelerating M-CSF Receptor c-Fms Degradation in Osteoclast Differentiation.
    Lee K; Kim MY; Ahn H; Kim HS; Shin HI; Jeong D
    Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28946669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical role of beta3 integrin in experimental postmenopausal osteoporosis.
    Zhao H; Kitaura H; Sands MS; Ross FP; Teitelbaum SL; Novack DV
    J Bone Miner Res; 2005 Dec; 20(12):2116-23. PubMed ID: 16294265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific targeting of PKCδ suppresses osteoclast differentiation by accelerating proteolysis of membrane-bound macrophage colony-stimulating factor receptor.
    Kim MY; Lee K; Shin HI; Jeong D
    Sci Rep; 2019 May; 9(1):7044. PubMed ID: 31065073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. M-CSF induces the stable interaction of cFms with alphaVbeta3 integrin in osteoclasts.
    Elsegood CL; Zhuo Y; Wesolowski GA; Hamilton JA; Rodan GA; Duong LT
    Int J Biochem Cell Biol; 2006; 38(9):1518-29. PubMed ID: 16600665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyrosines 559 and 807 in the cytoplasmic tail of the macrophage colony-stimulating factor receptor play distinct roles in osteoclast differentiation and function.
    Feng X; Takeshita S; Namba N; Wei S; Teitelbaum SL; Ross FP
    Endocrinology; 2002 Dec; 143(12):4868-74. PubMed ID: 12446614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psoralen and Bakuchiol Ameliorate M-CSF Plus RANKL-Induced Osteoclast Differentiation and Bone Resorption Via Inhibition of AKT and AP-1 Pathways in Vitro.
    Chai L; Zhou K; Wang S; Zhang H; Fan N; Li J; Tan X; Hu L; Fan X
    Cell Physiol Biochem; 2018; 48(5):2123-2133. PubMed ID: 30110702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-c-Fms antibody inhibits lipopolysaccharide-induced osteoclastogenesis in vivo.
    Kimura K; Kitaura H; Fujii T; Hakami ZW; Takano-Yamamoto T
    FEMS Immunol Med Microbiol; 2012 Mar; 64(2):219-27. PubMed ID: 22067001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of Dusp14 protects against osteoclast generation and bone loss by regulating AMPKα-dependent manner.
    Hong L; Ai J; Ma D
    Biochem Biophys Res Commun; 2019 Nov; 519(3):445-452. PubMed ID: 31526569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
    Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
    Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. alphavbeta3 and macrophage colony-stimulating factor: partners in osteoclast biology.
    Ross FP; Teitelbaum SL
    Immunol Rev; 2005 Dec; 208():88-105. PubMed ID: 16313343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-214 promotes osteoclastogenesis by targeting Pten/PI3k/Akt pathway.
    Zhao C; Sun W; Zhang P; Ling S; Li Y; Zhao D; Peng J; Wang A; Li Q; Song J; Wang C; Xu X; Xu Z; Zhong G; Han B; Chang YZ; Li Y
    RNA Biol; 2015; 12(3):343-53. PubMed ID: 25826666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Vitaxin, a novel therapeutic in trial for metastatic bone tumors, on osteoclast functions in vitro.
    Gramoun A; Shorey S; Bashutski JD; Dixon SJ; Sims SM; Heersche JN; Manolson MF
    J Cell Biochem; 2007 Oct; 102(2):341-52. PubMed ID: 17390341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The MET/Vascular Endothelial Growth Factor Receptor (VEGFR)-targeted Tyrosine Kinase Inhibitor Also Attenuates FMS-dependent Osteoclast Differentiation and Bone Destruction Induced by Prostate Cancer.
    Watanabe K; Hirata M; Tominari T; Matsumoto C; Fujita H; Yonekura K; Murphy G; Nagase H; Miyaura C; Inada M
    J Biol Chem; 2016 Sep; 291(40):20891-20899. PubMed ID: 27539855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Premature expression of the macrophage colony-stimulating factor receptor on a multipotential stem cell line does not alter differentiation lineages controlled by stromal cells used for coculture.
    Kinashi T; Lee KH; Ogawa M; Tohyama K; Tashiro K; Fukunaga R; Nagata S; Honjo T
    J Exp Med; 1991 May; 173(5):1267-79. PubMed ID: 1708812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.